<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefiderocol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefiderocol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefiderocol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="126254" href="/d/html/126254.html" rel="external">see "Cefiderocol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54124311"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fetroja</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53843618"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Cephalosporin</li></ul></div>
<div class="block doa drugH1Div" id="F53872645"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Not recommended for routine empiric use. Reserve for patients with or at risk for certain extensively drug-resistant gram-negative pathogens (nonsusceptible to ≥1 agent in all but 2 or fewer antimicrobial classes) (eg, carbapenem-resistant <i>Acinetobacter baumannii</i> or Enterobacterales, <i>P.</i>
<i>aeruginosa </i>with difficult-to-treat resistance<i>, Stenotrophomonas maltophilia</i>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33058795','lexi-content-ref-34864936','lexi-content-ref-35439291','lexi-content-ref-21793988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33058795','lexi-content-ref-34864936','lexi-content-ref-35439291','lexi-content-ref-21793988'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for when preferred extended-spectrum agents cannot be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33058795','lexi-content-ref-34864936','lexi-content-ref-35439291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33058795','lexi-content-ref-34864936','lexi-content-ref-35439291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33058795','lexi-content-ref-33058798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33058795','lexi-content-ref-33058798'])">Ref</a></span>). Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>). <b>Note:</b> For patients with CrCl ≥120 mL/minute, increase dose to 2 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33058795','lexi-content-ref-33058798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33058795','lexi-content-ref-33058798'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 8 hours. Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021','lexi-content-ref-30509675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021','lexi-content-ref-30509675'])">Ref</a></span>). <b>Note:</b> For patients with CrCl ≥120 mL/minute, increase dose to 2 g every 6 hours.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F53872647"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: Note:</b> Kidney function may be estimated using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥120 mL/minute: 2 g every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 60 to &lt;120 mL/minute: 2 g every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to &lt;60 mL/minute: 1.5 g every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to &lt;30 mL/minute: 1 g every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: 750 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (three times weekly):</b>
<b>IV:</b> Dialyzable (~60% in a 3- to 4-hour hemodialysis session): 750 mg every 12 hours; dose should be given immediately after hemodialysis on dialysis days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Dosing is based on effluent flow rate and is intended as initial dosing in patients receiving CRRT; dosing may need adjusted based on residual renal function and patient’s clinical status.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: <b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Effluent flow rate ≤2 L/hour: 1.5 g every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Effluent flow rate 2.1 to 3 L/hour: 2 g every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Effluent flow rate 3.1 to 4 L/hour: 1.5 g every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Effluent flow rate ≥4.1 L/hour: 2 g every 8 hours.</p></div>
<div class="block doha drugH1Div" id="F53872648"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F53872646"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F53848043"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (&lt;2%), bradycardia (&lt;2%), cardiac failure (&lt;2%), peripheral edema (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (2%), insomnia (&lt;2%), restlessness (&lt;2%), seizure (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (3%), pruritus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (2%), hypervolemia (&lt;2%), hypocalcemia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (4%), constipation (3%), nausea (2%), vomiting (2%), abdominal pain (&lt;2%), biliary colic (&lt;2%), cholecystitis (&lt;2%), cholelithiasis (&lt;2%), <i>Clostridioides difficile </i>associated diarrhea (&lt;2%), decreased appetite (&lt;2%), dysgeusia (&lt;2%), stomatitis (&lt;2%), xerostomia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Finding of blood in urine (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased INR (&lt;2%), prolonged prothrombin time (&lt;2%), thrombocythemia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug-induced hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion site reaction (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (2%), dyspnea (&lt;2%), pleural effusion (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&lt;2%)</p></div>
<div class="block coi drugH1Div" id="F53843621"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe hypersensitivity to cefiderocol, other beta-lactam antibacterial drugs, or any other component of the formulation.</p></div>
<div class="block war drugH1Div" id="F53872631"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious, sometimes fatal, hypersensitivity reactions may occur. Use caution in patients with a history of penicillin, cephalosporin, or other beta-lactam sensitivity; cross-hypersensitivity may occur. If a hypersensitivity reaction occurs, discontinue therapy and institute supportive measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Neurological reactions have been reported with cephalosporins, including encephalopathy, coma, asterixis, neuromuscular excitability, myoclonia, and nonconvulsive status epilepticus. Risk may be increased in patients with a history of seizure disorders and/or in the presence of renal impairment; ensure dose adjusted for renal function. If neurotoxicity occurs, obtain a neurological evaluation to determine if cefiderocol should be discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>Clostridioides</i>
<i>difficile</i>–associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment (CrCl ≤60 mL/minute); dosage adjustments recommended. May increase risk of neurotoxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Increased mortality was seen among critically ill patients receiving cefiderocol compared to recipients of best available therapy (most often containing colistin) for the treatment of carbapenem-resistant gram-negative bacterial infections, including pneumonia, bloodstream infection, and sepsis. The cause of the increase in mortality has not been established; closely monitor response to therapy in patients treated with cefiderocol.</p></div>
<div class="block foc drugH1Div" id="F54124312"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fetroja: 1 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F54124310"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54172944"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Fetroja Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $263.59</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F53872649"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer by intermittent IV infusion over 3 hours.</p></div>
<div class="block use drugH1Div" id="F53843620"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired and ventilator-associated:</b> Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: <i>Acinetobacter baumannii</i> complex, <i>Escherichia coli</i>, <i>Enterobacter cloacae</i> complex, <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i>, and <i>Serratia marcescens</i>, in patients ≥18 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b> Treatment of complicated urinary tract infections, including pyelonephritis, caused by the following susceptible gram-negative microorganisms: <i>E. coli</i>, <i>K. pneumoniae</i>, <i>Proteus mirabilis</i>, <i>P. aeruginosa</i>, and <i>E. cloacae</i> complex, in patients ≥18 years of age.</p></div>
<div class="block cyt drugH1Div" id="F53894257"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53894254"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F53872629"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In general, an increase in most types of birth defects or adverse maternal or fetal outcomes was not found following exposure to cephalosporins.</p></div>
<div class="block brc drugH1Div" id="F53872630"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if cefiderocol is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F53872651"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>
<div class="block pha drugH1Div" id="F53872636"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cefiderocol is a siderophore cephalosporin. A catechol side chain promotes formation of chelated complexes with ferric iron, allowing use of iron transport systems to deliver cefiderocol across the outer membrane of gram-negative bacilli. The cephalosporin moiety binds to penicillin-binding proteins which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis.</p></div>
<div class="block phk drugH1Div" id="F53872637"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 18 (±3.36) L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 40% to 60% (primarily to albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimal.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: 98.6% (90.6% as unchanged drug); feces: 2.8%.</p></div>
<div class="block phksp drugH1Div" id="F53872643"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC increased 1.37-, 2.35-, 3.21-, and 4.69-fold in patients with CrCl 60 to 89 mL/minute, 30 to 59 mL/minute, 15 to 29 mL/minute, and &lt;15 mL/minute, respectively, compared to patients with CrCl 90 to 119 mL/minute. Patients with CrCl ≥120 mL/minute experience increased cefiderocol clearance. Approximately 60% of cefiderocol is removed by a 3- to 4-hour hemodialysis session.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration. Goal: ≥ ~75% (range 55% to 88%) (Katsube 2019; Nakamura 2019; Principe 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in patients with normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Adults: C<sub>max</sub> (peak): IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Single dose: 2 g IV: 156 mcg/mL (Saisho 2018).</p>
<p style="text-indent:-2em;margin-left:8em;">Steady state: 2 g every 8 hours: 153 mcg/mL (Saisho 2018).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56521965"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fetcroja</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fetroja</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fetcroja</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fetcroja</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fetcroja</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fetcroja</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fetcroja</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fetcroja | Fetroja</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fetcroja</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fetcroja</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fetcroja</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33058795">
<a name="33058795"></a>Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. <i>Lancet Infect Dis</i>. 2021;21(2):226-240. doi:10.1016/S1473-3099(20)30796-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/33058795/pubmed" id="33058795" target="_blank">33058795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fetroja.1">
<a name="Fetroja.1"></a>Fetroja (cefiderocol) [prescribing information]. Florham Park, NJ: Shionogi Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021">
<a name="Hooton.2021"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31724042">
<a name="31724042"></a>Katsube T, Echols R, Wajima T. Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin. <i>Clin Infect Dis</i>. 2019;69(suppl 7):S552-S558. doi:10.1093/cid/ciz828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/31724042/pubmed" id="31724042" target="_blank">31724042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21793988">
<a name="21793988"></a>Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. <i>Clin Microbiol Infect</i>. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/21793988/pubmed" id="21793988" target="_blank">21793988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31262762">
<a name="31262762"></a>Nakamura R, Ito-Horiyama T, Takemura M, et al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in Murine thigh and lung infection models. <i>Antimicrob Agents Chemother.</i> 2019;63(9):e02031-18. doi:10.1128/AAC.02031-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/31262762/pubmed" id="31262762" target="_blank">31262762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30509675">
<a name="30509675"></a>Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. <i>Lancet Infect Dis</i>. 2018;18(12):1319-1328. doi:10.1016/S1473-3099(18)30554-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/30509675/pubmed" id="30509675" target="_blank">30509675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35455461">
<a name="35455461"></a>Principe L, Lupia T, Andriani L, et al. Microbiological, clinical, and PK/PD features of the new anti-gram-negative antibiotics: β-lactam/β-lactamase inhibitors in combination and cefiderocol-an all-inclusive guide for clinicians.<i> Pharmaceuticals (Basel)</i>. 2022;15(4):463. doi:10.3390/ph15040463<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/35455461/pubmed" id="35455461" target="_blank">35455461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Quale.2021">
<a name="Quale.2021"></a>Quale J, Spelman D. Overview of carbapenemase-producing gram-negative bacilli. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29311072">
<a name="29311072"></a>Saisho Y, Katsube T, White S, Fukase H, Shimada J. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative bacteria, in healthy subjects. <i>Antimicrob Agents Chemother.</i> 2018;62(3):e02163-17. doi:10.1128/AAC.02163-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/29311072/pubmed" id="29311072" target="_blank">29311072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia Infections. <i>Clin Infect Dis</i>. 2022a;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35439291">
<a name="35439291"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). <i>Clin Infect Dis</i>. 2022b;75(2):187-212. doi:10.1093/cid/ciac268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/35439291/pubmed" id="35439291" target="_blank">35439291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33058798">
<a name="33058798"></a>Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet Infect Dis</i>. 2021;21(2):213-225. doi:10.1016/S1473-3099(20)30731-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefiderocol-drug-information/abstract-text/33058798/pubmed" id="33058798" target="_blank">33058798</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 126182 Version 62.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
